m14

RHPS4 (RHPS 4 methosulfate) is a potent inhibitor of Telomerase at submicromolar.

Anti-IGFBP2 Antibody (M14) is a human monoclonal antibody inhibitor that binds with high affinity to IGFBP2 and prevents its interaction with IGF1. Additionally, Anti-IGFBP2 Antibody (M14) can inhibit the recruitment of human endothelial cells, thereby obstructing tumor progression in human metastatic cancers.

RBM14C12 is a compound known for its cell signaling activity. It plays a crucial role in researching lipid metabolism and cell membrane structure. Additionally, RBM14C12 can be utilized in the development of novel compounds aimed at modulating the biological mechanisms associated with lipid-related diseases.

DSM1465 (Compound 82) is a potent and selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 value of 15 nM. It inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC50 value of 1.4 nM and demonstrates significant in vivo efficacy in humanized P. falciparum mouse models.

BDM14471 is a selective inhibitor of hydroxamate PfAM1.

GEM144 is a potent, orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC 11. GEM144 induces p53 acetylation, activates p21, blocks the cell cycle in G1/S phase and induces apoptosis.

NCATS-SM1440 is a Lactate Dehydrogenase Inhibitor with Optimized Cell Activity and Pharmacokinetic Properties.

HlyU inhibitor CM14 (1025E12) is a useful organic compound for research related to life sciences. The catalog number is T8791 and the CAS number is 588678-13-1.

M145724 ((3Z,6E)-1-N-Methylalbonoursin) is a metabolite that can be extracted from Streptomyces albus.

(R)-Carvedilol is a non-selective blocker of β/α-1. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

(S)-Carvedilol is a non-selective β/α-1 blocker.It exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

Azetirelin (YM 14673) is a new thyrotropin-releasing hormone (TRH) analog.

Lem-14-1189, a LEM-14 derivative, is a potent NSD inhibitor of the nuclear receptor binding SET domain, and has inhibitory effects on NSD1, NSD2, and NSD3, with IC50 of 418 μM, 111 μM, and 60 μM, respectively. LEM-14-1189 has potential anticancer activity and can be used to study multiple myeloma (MM) and diseases of the blood system.

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and no intrinsic sympathomimetic activity.

Carvedilol (SKF 105517) Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.

Mifepristone (C-1073) is a progesterone-receptor (IC50=0.2 nM) and glucocorticoid-receptor antagonist (IC50=2.6 nM). Mifepristone is used to terminate pregnancy, treat uterine fibroids, and treat endometriosis.

Camptothecin (CPT) belongs to the alkaloid group of natural products and is a specific DNA topoisomerase I (Topo I) inhibitor (IC50=679 nM) with specificity. Camptothecin has antitumor activity and induces apoptosis.

VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells.

ISAM-140 is a potent and highly selective antagonist of A2B adenosine receptor.

LEM-14 is a potent NSD2-specific inhibitor (IC50:132 μM).LEM-14 may be used in the study of multiple myeloma.

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity, showing potential as a first-in-class candidate in AML [Acute Myeloid Leukemia].

Dehydroaripiprazole (DM-14857) is the active metabolite of aripiprazole. Aripiprazole is an antipsychotic drug, which is metabolized by CYP3A4 and CYP2D6 and mainly forms dehydroaripiprazole. Dehydroaripiprazole has antipsychotic activity equivalent to aripiprazole.

LM-1484 displays a higher affinity for 3H-LTC4 sites and is an antagonist of CysLT1 receptor.

TNP-470 is a methionine aminopeptidase-2 inhibitor and an angiogenesis inhibitor.